IP Group portfolio company begins phase two trial of arthritis drug
(Alliance News) - IP Group PLC on Wednesday reported that its majority-owned portfolio company, Istesso Ltd, has begun a phase 2b trial of its lead drug, MBS2320, in rheumatoid arthritis. Read More